RESOURCES | BLOG
April 5, 2026

Remote Heart Failure Monitoring Devices: 2026 Guide

Compare top remote heart failure monitoring devices for 2026. Rhythm360 unifies your RPM program with expert support. See the full breakdown.

Last updated: October 16, 2026

Key Takeaways

  • Remote heart failure monitoring devices fall into two main categories: implantable pulmonary artery pressure sensors for higher-acuity NYHA Class III patients and non-invasive RPM kits or wearables for broader, lower-acuity populations.
  • Patient acuity, staffing capacity, and reimbursement pathways drive the choice between implantable sensors and non-invasive monitoring solutions.
  • Implantable PA sensors bill under CPT 93297 with CMS Coverage with Evidence Development, while non-invasive RPM programs use the expanded 2026 RPM CPT code family, including new codes 99445 and 99470.
  • Alert fatigue and patient adherence remain key operational challenges and require AI-powered triage plus automated workflows to avoid missed clinical events.
  • Rhythm360 unifies implantable and non-invasive heart failure monitoring data in a single vendor-neutral platform that can reduce alert response times by up to 80% and improve revenue capture by up to 300%.

See How Rhythm360 Unifies Your HF Monitoring

1. Implantable Pulmonary Artery Pressure Monitors: CardioMEMS and Cordella

Implantable pulmonary artery pressure monitors sit at the higher-acuity end of remote heart failure monitoring. These devices are implanted via right heart catheterization and measure pulmonary artery pressure directly, detecting congestion weeks before physical symptoms such as weight gain or dyspnea appear.

CardioMEMS (Abbott) received initial FDA premarket approval (PMA P100045) in May 2014 for NYHA Class III heart failure patients hospitalized for heart failure within the previous year. In 2022, the FDA expanded the CardioMEMS indication to selected NYHA Class II and III patients with a prior heart failure hospitalization and/or elevated natriuretic peptide levels. The implanted sensor has no conventional battery and is designed for long-term, potentially indefinite use. External patient electronics such as the reader, antenna, and dock are the components most likely to need replacement or servicing, so practices should budget for those lifecycle costs separately.

Cordella (Endotronix/Edwards Lifesciences) received FDA Premarket Approval P230040 in June 2024 for NYHA Class III heart failure patients at home on diuretics and guideline-directed medical therapy who have been stable for 30 days. The Cordella system includes an implantable sensor placed in the right pulmonary artery, a handheld patient reader, and a data analysis platform that interfaces with Bluetooth-connected peripherals for weight, heart rate, systolic blood pressure, and SpO2 monitoring. The pivotal PROACTIVE-HF trial reported a six-month heart failure hospitalization or all-cause mortality rate of 0.1589 events per patient, significantly below the prespecified performance goal of 0.43.

Both devices generate data billable under CPT 93297, the implantable cardiovascular physiologic monitor code. CPT 93297 applies once per 30 days and can be split into professional (-26) and technical (-TC) components. Implantable PA sensors typically follow a CMS Coverage with Evidence Development pathway, so practices should confirm current coverage criteria with their Medicare Administrative Contractor.

2. Non-Invasive RPM Kits and Wearables: Cadence, Optimize Health, HRS, Bodyport, and Biobeat

Non-invasive remote patient monitoring kits and wearables support broader, lower-acuity heart failure populations. These programs often focus on post-discharge patients or those with NYHA Class I–II disease who need daily vital sign tracking without invasive procedures.

Cadence offers a cellular-connected kit that transmits weight, blood pressure, heart rate, and symptom data to clinician portals without requiring patient smartphone use. Optimize Health provides a similar cellular RPM kit with automated data transmission and EHR integration. HRS (Health Recovery Solutions) delivers a patient engagement platform with Bluetooth-enabled scales, blood pressure cuffs, and pulse oximeters that stream data to a clinician dashboard. Bodyport uses an FDA-cleared scale with ballistocardiography to measure cardiac biomarkers including heart rate and fluid status through standing weight measurement. Biobeat offers a wearable patch that continuously monitors blood pressure, heart rate, oxygen saturation, and temperature.

These kits generally bill under the RPM CPT code family. Seven CPT codes govern remote patient monitoring billing in 2026: 99453, 99454, 99445, 99457, 99470, 99458, and 99091. They fall into two functional groups. The first group covers device setup and supply: 99453 pays for initial setup and patient education once per episode of care, while 99454 and 99445 pay for device supply based on how many days of data are transmitted in a 30-day period. The second group covers treatment management time: 99457, 99470, and 99458 reimburse for clinician time spent managing data and communicating with patients.

Medicare paid $536 million for remote patient monitoring in 2024, a 31 percent increase over the prior year, according to the HHS Office of Inspector General's August 2025 data snapshot on RPM billing. This growth highlights both the revenue opportunity and the compliance scrutiny that practices should expect.

Explore Rhythm360 for Non-Invasive RPM

3. Decision Framework: Choose the Category Before the Vendor

Practices gain clarity when they choose a monitoring category before comparing individual vendors. A simple gating framework helps match patients and workflows to the right approach.

Step 1: Patient Acuity Assessment. NYHA class and recent hospitalization history determine candidacy for an implantable PA sensor. CardioMEMS is indicated for NYHA Class II–III patients with prior hospitalization or elevated natriuretic peptides. Cordella is approved for NYHA Class III patients who have been stable on diuretics and guideline-directed medical therapy for 30 days. Non-invasive RPM kits serve broader populations, including NYHA Class I–II patients and those in post-discharge monitoring.

Step 2: Staffing Capacity Evaluation. Implantable PA sensor programs require procedural infrastructure for implantation and ongoing hemodynamic data review. Non-invasive RPM programs generate higher alert volumes across larger patient panels and need either dedicated clinical staff or AI-powered triage to prevent alert fatigue. Operational policies for implantable-device remote monitoring should specify alert types and thresholds, review schedules, standard operating procedures, coverage hours, and how findings reach the responsible physician.

Step 3: EHR and Device Ecosystem Integration. Practices with existing CIED programs benefit from platforms that consolidate data from multiple OEM portals. Bi-directional EHR integration determines whether data flows into daily workflows or adds documentation burden. The table below summarizes how implantable and non-invasive categories differ across the main decision factors.

Attribute Implantable PA Pressure Sensors Non-Invasive RPM Kits
What It Measures Pulmonary artery pressure and heart rate via implanted sensor Weight, blood pressure, heart rate, SpO2, and related physiologic parameters
Typical Patient Acuity NYHA Class II–III with prior HF hospitalization or elevated natriuretic peptides NYHA Class I–II, post-discharge, or broader chronic disease populations
Who Reviews Data HF program leads, cardiologists, advanced practice providers RNs, medical assistants, clinical staff under general supervision
Reimbursement Pathway CMS Coverage with Evidence Development; CPT 93297 (once per 30 days, splittable into -26/-TC components) RPM CPT codes 99453, 99454, 99445, 99457, 99470, 99458

4. Operational Reality: Who Reviews the Data and How Alerts Escalate

Once a practice chooses a category, the next step is defining who reviews data and how alerts move through the team. Clear roles and escalation rules keep programs safe and sustainable.

In implantable PA sensor programs, HF program coordinators or device technicians typically handle enrollment, while RNs, CCTs, NPs, or physicians review data. Alert escalation follows a tiered protocol. Teams review routine transmissions on a scheduled cadence, and they escalate urgent alerts such as rising PA pressures that suggest decompensation within hours. In the TRUST study, the median time from detection of arrhythmia events to medical intervention was 1 day in the remote monitoring group versus 35.5 days in the ambulatory treatment group. This difference shows the impact of structured escalation protocols.

Non-invasive RPM programs manage higher alert volumes across larger patient panels. Without intelligent triage, alert fatigue develops as clinicians dismiss notifications and risk missing critical events. AI-driven triage and optional certified cardiac technician oversight can filter non-actionable noise and highlight clinically significant events.

Rhythm360 supports these workflows by consolidating CIED and HF/HTN data in one vendor-neutral dashboard and integrating bi-directionally with Epic, Cerner, Athenahealth, eClinicalWorks, and Greenway Health. University of Chicago Medicine reviewed more than 73,000 reports annually through Rhythm360 in calendar year 2025, averaging more than 18,000 reports per quarter, which demonstrates scalability for high-volume practices. As one UCM clinician noted, "We have improved billing and accountability for our patients after the integration."

Rhythm360
Rhythm360

Streamline Your Alert Review With Rhythm360

5. Reimbursement Pathways: Implantable Devices and RPM Codes

Clear reimbursement pathways keep remote heart failure monitoring programs financially sustainable. Implantable PA pressure sensors follow one set of rules, while non-invasive RPM kits follow another.

For implantable devices, CPT 93297 covers implantable cardiovascular physiologic monitors such as CardioMEMS. Practices can bill this code once per 30 days and split it into professional (-26) and technical (-TC) components. CPT 93298 covers subcutaneous cardiac rhythm monitors and implantable loop recorders with the same 30-day billing cycle. For pacemakers and ICDs on the 90-day cycle, CPT 93294 (pacemaker professional), 93295 (ICD professional), and 93296 (technical) apply.

For non-invasive RPM, the 2026 code set expands coverage. CMS's CY2026 Physician Fee Schedule final rule added codes 99445 and 99470 to close billing gaps that existed since RPM codes were introduced. Approximate 2026 national-average, non-facility Medicare Physician Fee Schedule rates are: 99453 around $22 (one-time), 99454 around $52, 99445 around $52, 99457 around $52, 99470 around $26, and 99458 around $41. These rates provide a starting point for financial modeling.

Practices should also track proposed regulatory changes. On July 14, 2026, CMS issued the Calendar Year 2027 Medicare Physician Fee Schedule Proposed Rule, which proposes to allow payment for RPM services only when performed by clinical staff employed by the billing practice and to require a separately reported face-to-face initiating visit before RPM services begin. These proposals may change before finalization, so teams should confirm the final CMS rule and payer guidance before revising workflows.

Rhythm360 supports reimbursement by automating CPT code capture and documentation, which helps practices recover revenue that previously went unbilled.

6. Honest Limitations of Remote Heart Failure Monitoring

Remote heart failure monitoring delivers value but also carries real limitations. Patient adherence and connectivity failures sit at the top of that list. Patients may forget daily readings, scales can lose cellular connection, and Bluetooth pairing can fail. The HHS Office of Inspector General's August 2025 RPM billing data snapshot flagged enrollment spikes, device charges without corresponding management time, and overlapping claims from multiple providers as patterns warranting further review. These compliance risks grow when programs lack centralized documentation.

Alert fatigue is a second major limitation. An analysis of the global Home Monitoring database including 11,624 patients reported a total of 3,004,763 alerts, with more than 60% of alerts from pacemakers and CRT-Ds due to atrial fibrillation. This volume makes intelligent triage essential. Programs also incur operational costs, including staff time for enrollment, data review, and patient follow-up.

Thoughtful platform and workflow design can address many of these issues. Automated patient reminders and redundant data feeds support adherence and data completeness. AI-powered alert triage helps teams focus on the highest-risk events. As Andrew Beaser, MD, Associate Professor of Medicine at University of Chicago Medicine, observed after implementing Rhythm360, decision support and AI-assisted tools grow more important as data volumes increase.

7. Pre-Purchase Checklist: Six Questions to Ask Every Vendor

A structured vendor checklist keeps purchasing decisions aligned with clinical, operational, and financial goals. Before signing a contract, ask every vendor these six questions:

  1. What is the FDA-cleared indication and patient eligibility criteria?
  2. How does the device transmit data, and what happens if connectivity fails?
  3. Does the platform integrate bi-directionally with our EHR?
  4. Who reviews alerts, and what is the escalation protocol?
  5. Which CPT codes does the system capture, and how does it document them?
  6. What is the onboarding timeline and total cost of ownership?

Rhythm360 addresses each of these areas. The platform is vendor-neutral and HIPAA-compliant and achieves greater than 99.9% data transmissibility through redundant data feeds, computer vision, and AI-powered extrapolation. Onboarding, including EHR integration, typically takes from a few days to a few weeks. Other platforms in the remote cardiac monitoring space, including Murj, Implicity, Rhythm Management Group, and Octagos, provide additional options for comparison.

Compare Your Requirements With Rhythm360

Conclusion: Unify Your Heart Failure Monitoring Program

Remote heart failure monitoring programs often stall because of fragmented OEM portals and disconnected workflows, even when devices perform well. Practices that choose the right device category for their population and then unify data management across implantable and non-invasive modalities achieve more consistent clinical and financial results. Rhythm360 offers a vendor-neutral, AI-powered platform that consolidates CIED and HF/HTN data and delivers the alert response and revenue capture improvements highlighted earlier.

For additional context on building a remote heart failure monitoring program, see 6 Strategies for Better Remote Monitoring for Heart Failure Management, Best Practices for Remote Monitoring in Heart Failure, and Remote Heart Failure Monitoring: Platforms & Coverage.

Frequently Asked Questions

How Long Does a CardioMEMS Device Last?

The implanted CardioMEMS sensor has no conventional battery and is designed for long-term, potentially indefinite use. The external patient electronics, including the reader, antenna, and dock, are more likely to require replacement or servicing over time. Practices planning a CardioMEMS program should budget for external equipment maintenance separately and consult Abbott's current product documentation for detailed lifecycle guidance.

Does Medicare Cover Implantable Pulmonary Artery Pressure Sensors?

Implantable PA pressure sensors such as CardioMEMS and Cordella typically follow a CMS Coverage with Evidence Development pathway that conditions coverage on participation in an approved registry or clinical study. Coverage criteria, registry requirements, and applicable billing codes can vary by Medicare Administrative Contractor. Practices should verify current national and local coverage determinations with their MAC before enrolling patients and submitting claims under CPT 93297.

What Is One Disadvantage of Remote Patient Monitoring for Heart Failure?

Patient adherence and connectivity failures are among the most common challenges. Patients may miss daily readings, devices can lose cellular or Bluetooth connectivity, and data gaps can disrupt billing eligibility, particularly for CPT 99454, which requires at least 16 days of data transmission in a 30-day period. Alert fatigue is another major disadvantage. When monitoring systems lack intelligent triage, clinicians receive many non-actionable notifications and may begin dismissing alerts, which increases the risk of missing clinically significant events.

How Do You Choose Between Implantable and Non-Invasive Heart Failure Monitoring?

Patient acuity serves as the primary gating criterion. NYHA Class II–III patients with a recent heart failure hospitalization or elevated natriuretic peptides may qualify for implantable PA pressure sensors under current FDA indications. Broader, lower-acuity populations, including NYHA Class I–II patients and those in post-discharge transition programs, are generally better served by non-invasive RPM kits. Staffing capacity forms the second criterion. Implantable sensor programs require procedural infrastructure and hemodynamic expertise, while non-invasive RPM programs require clinical staff capacity to manage higher alert volumes across larger panels. Reimbursement pathway clarity, including CMS Coverage with Evidence Development for implantable sensors and RPM CPT codes for non-invasive kits, should inform financial modeling before vendor selection.

What CPT Codes Apply to Remote Heart Failure Monitoring in 2026?

The applicable codes depend on the monitoring category. For implantable cardiovascular physiologic monitors such as CardioMEMS, CPT 93297 applies once per 30 days and can be split into professional (-26) and technical (-TC) components. For subcutaneous cardiac rhythm monitors and implantable loop recorders, CPT 93298 applies under the same billing structure. For pacemakers and ICDs on the 90-day cycle, CPT 93294 (pacemaker professional), 93295 (ICD professional), and 93296 (technical) apply. For non-invasive RPM programs, the 2026 code set includes CPT 99453 (device setup, once per episode of care), 99454 (device supply with 16 or more days of data per 30-day period), 99445 (device supply with 2 to 15 days of data, new for 2026), 99457 (first 20 minutes of treatment management per calendar month), 99470 (first 10 to 19 minutes of treatment management, new for 2026), and 99458 (each additional 20 minutes of treatment management). Incorrect code pairing, such as billing both 99454 and 99445 in the same 30-day period or both 99457 and 99470 in the same calendar month, triggers automatic mutual-exclusivity denials and remains one of the most common RPM billing errors.

Read Next

Related posts